HighTower Advisors LLC lessened its stake in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 25.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,376 shares of the company’s stock after selling 9,524 shares during the period. HighTower Advisors LLC’s holdings in Guardant Health were worth $2,898,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of GH. V Square Quantitative Management LLC purchased a new stake in Guardant Health in the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC purchased a new stake in Guardant Health in the 4th quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Guardant Health in the 4th quarter worth approximately $31,000. Elyxium Wealth LLC purchased a new stake in Guardant Health in the 4th quarter worth approximately $35,000. Finally, First Pacific Financial purchased a new stake in Guardant Health in the 4th quarter worth approximately $43,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.
Guardant Health Stock Down 2.6%
Shares of NASDAQ:GH opened at $129.69 on Friday. The business has a fifty day moving average of $95.08 and a two-hundred day moving average of $99.94. The stock has a market cap of $17.20 billion, a P/E ratio of -38.26 and a beta of 1.48. Guardant Health, Inc. has a 52-week low of $38.03 and a 52-week high of $133.97.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on Guardant Health
Insider Activity at Guardant Health
In other Guardant Health news, insider Terilyn J. Monroe sold 3,832 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $92.68, for a total value of $355,149.76. Following the sale, the insider owned 20,990 shares of the company’s stock, valued at $1,945,353.20. This trade represents a 15.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John G. Saia sold 20,000 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total value of $2,130,200.00. Following the completion of the sale, the insider directly owned 45,950 shares in the company, valued at $4,894,134.50. This represents a 30.33% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 332,244 shares of company stock worth $36,156,026 over the last ninety days. Company insiders own 5.60% of the company’s stock.
Guardant Health Company Profile
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Featured Stories
- Five stocks we like better than Guardant Health
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
